Verona Pharma PLC Exercise of options (0739L)
September 28 2016 - 5:49AM
UK Regulatory
TIDMVRP
RNS Number : 0739L
Verona Pharma PLC
28 September 2016
Verona Pharma plc
("Verona Pharma" or the "Company")
Exercise of Options
The Company announces that it has issued 166,667 new ordinary
shares in the capital of the Company (the "New Shares") following
an exercise of share options by an employee. Application has been
made to the London Stock Exchange for the New Shares to be admitted
to trading on AIM, with dealings expected to commence on 4 October
2016 ("Admission").
Following Admission, the Company will have a total of
2,565,886,493 Ordinary Shares in issue each carrying one voting
right. The Company does not hold any Ordinary Shares in Treasury.
This figure of 2,565,886,493 Ordinary Shares may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the share capital of the Company
under the FCA's Disclosure and Transparency Rules.
For further information please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer
N+1 Singer (Nominated Adviser and Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer
FTI Consulting Tel: +44 (0)20 3727 1000
Simon Conway/Stephanie Cuthbert/Natalie Garland-Collins
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical
company focused on the development of innovative prescription
medicines to treat respiratory diseases with significant unmet
medical needs, such as chronic obstructive pulmonary disease
(COPD), asthma and cystic fibrosis.
Verona Pharma's lead drug, RPL554, is a first-in-class drug in
Phase 2 trials as a nebulised treatment for acute exacerbations of
COPD in the hospital setting. The drug is a dual phosphodiesterase
(PDE) 3/4 inhibitor and therefore has both bronchodilator and
anti-inflammatory effects, which are essential to the improvement
of patients with COPD and asthma.
Verona Pharma is also building a broader portfolio of
RPL554-containing products to maximise its benefit to patients and
its value. This includes the very significant markets for COPD and
asthma maintenance therapy. The Company is also exploring the
potential of the drug in different diseases, such as cystic
fibrosis, where it is in pre-clinical testing and has received a
Venture and Innovation Award from the Cystic Fibrosis Trust.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEGCGDCRSDBGLI
(END) Dow Jones Newswires
September 28, 2016 05:49 ET (09:49 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024